Prophylaxis with topical azithromycin against Lyme borreliosis

Affiliations

¹ Department of Pediatrics, Department of Epidemiology, and Department of Investigative Medicine, Yale University, New Haven, CT 06520-8064, USA. Electronic address: Eugene.Shapiro@Yale.edu.
² Division of Infectious Diseases, New York Medical College, Valhalla, NY, USA.

Comment

Eugene D Shapiro et al. Lancet Infect Dis. 2017 Mar.

. 2017 Mar;17(3):246-248.

doi: 10.1016/S1473-3099(16)30551-5. Epub 2016 Dec 20.

¹ Department of Pediatrics, Department of Epidemiology, and Department of Investigative Medicine, Yale University, New Haven, CT 06520-8064, USA. Electronic address: Eugene.Shapiro@Yale.edu.
² Division of Infectious Diseases, New York Medical College, Valhalla, NY, USA.

No abstract available

Comment on

Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial.
Schwameis M, Kündig T, Huber G, von Bidder L, Meinel L, Weisser R, Aberer E, Härter G, Weinke T, Jelinek T, Fätkenheuer G, Wollina U, Burchard GD, Aschoff R, Nischik R, Sattler G, Popp G, Lotte W, Wiechert D, Eder G, Maus O, Staubach-Renz P, Gräfe A, Geigenberger V, Naudts I, Sebastian M, Reider N, Weber R, Heckmann M, Reisinger EC, Klein G, Wantzen J, Jilma B. Schwameis M, et al. Lancet Infect Dis. 2017 Mar;17(3):322-329. doi: 10.1016/S1473-3099(16)30529-1. Epub 2016 Dec 20. Lancet Infect Dis. 2017. PMID: 28007428 Clinical Trial.